121 results on '"Scattoni, V"'
Search Results
2. Prostate volume is associated with optimal “trifecta” outcomes after holep – results from a prospective trial (EXPHO)
3. Prostate volume is associated with optimal TRIFECTA outcomes after HoLEP – results from a prospective trial (ExpHo)
4. Risk of orgasmic function impairment after HoLEP – findings of a prospective real-life trial (ExpHo)
5. Unfavourable outcomes after holmium laser enucleation of the prostate (HoLEP) are common also in the hands of a very esperienced surgeon – results from a prospective trial (ExpHo)
6. What results should you expect from holmium laser enucleation of the prostate after completing the surgeon’s learning curve? benchmark results from an experienced single surgeon series of patients with large prostate
7. Preoperative characteristics and surgical outcomes in patients submitted to holmium laser enucleation of the prostate (HoLEP) ten years ago vs. a contemporary cohort: a real-life analysis
8. Preoperative frailty status is a predictor of 90-days readmission in radical cystectomy candidates
9. Does prostate volume affect early continence recovery after holmium laser enucleation of the prostate? – Results from a prospective trial (ExpHo)
10. Unfavourable outcomes after Holmium Laser Enucleation of the Prostate (HoLEP) are common also in the hands of a very esperienced surgeon – Results from a prospective trial (ExpHo)
11. Does prostate volume affect early continence recovery after holmium laser enucleation of the prostate? Results from a prospective trial (ExpHo)
12. Limited vs extended lymph node dissection in T1G3 bladder cancer patients treated with radical cystectomy: is this group responsible for the negative results of the LEA trial?
13. Incongruence between turb and radical cystectomy findings in terms of histological variant identification: analysis of all potential clinical risk factors
14. Definition of a structured training curriculum for holmium laser enucleation of the prostate
15. Incongruence between TURB and radical cystectomy findings in terms of histological variant identification: Analysis of all potential clinical risk factors
16. Postoperative complications after holmium laser enucleation of the prostate in a high volume center with more than 15 years of experience
17. Which cancers are still diagnosed by standard prostate biopsy without an upfront multiparametric MRI? Results from a tertiary care, high volume centre
18. Postoperative complications after holmium laser enucleation of the prostate in a high volume center with more than 15 years of experience
19. Clinical comparison of holmium laser enucleation of the prostate (HoLEP) and bipolar transurethral enucleation of the prostate (BTUEP) in patients under either anticoagulation or antiplatelet therapy
20. Which cancers are still diagnosed by standard prostate biopsy without an upfront multiparametric MRI? Results from a tertiary care, high volume centre
21. Development and external validation of a novel model to indentify patients who can avoid systematic prostate biopsy in addition to mp-MRI targeted biopsies: Results from a two-center series
22. Which patients with clinically node prostate cancer benefit from radical prostatectomy? The impact of the size and site of nodal involvement on long-term outcomes
23. Central prostate biopsy revision at referral center is key for correct patient management: Results from a prospective, single center series
24. Prevalence and prognostic impact of prostate cancer histological variants at radical prostatectomy: A long-term, single center analysis
25. Pathological findings at radical prostatectomy after initial active surveillance in low-risk prostate cancer patients. Did we miss the chance to cure?
26. Can we modulate the extent of nodal dissection according to the preoperative risk of lymph node invasion in prostate cancer patients undergoing radical prostatectomy?
27. Predictors of early cancer specific and other cause mortality in high risk prostate cancer patients after radical prostatectomy: Results from a large, multi-institutional analysis
28. Is individual surgeon experience the optimal measure to assess learning curve during robot-assisted radical prostatectomy?
29. 546 Patterns of recurrence and long-term cancer-specific mortality of prostate cancer patients treated with salvage radical prostatectomy for radio-recurrent prostate cancer
30. 937 Prognostic value of tumour volume on disease progression of patients treated with radical prostatectomy for node positive prostate cancer
31. 930 [11C]Choline PET/CT predicts survival in hormone-naïve prostate cancer patients with biochemical failure after radical prostatectomy
32. 640 Head-to-head comparison of conditional oncological outcomes after radical prostatectomy in patients with intermediate and high risk prostate cancer
33. 186 Does surgical approach impact on the risk of positive surgical margin at radical prostatectomy in patients with clinically localized prostate cancer? A single institution analysis
34. 529 Time from surgery to urinary continence significantly influences the subsequent recovery of erectile function in patients treated with bilateral nerve-sparing radical prostatectomy
35. 825 Prostate health index (PHI) is more accurate than PCA3 assay in the prediction of aggressive characteristics at initial prostate biopsy (PBX)
36. 35 How to expand indications for active surveillance without compromising cancer control: A systematic assessment of the currently used criteria for prostate cancer patients
37. 36 Outcome of radical prostatectomy for misclassified active surveillance candidates
38. 744 The number of cores taken at first negative biopsy does not affect the cancer detection rate at saturation repeat biopsy in patients with persistent suspicion of prostate cancer
39. 289 Preoperative functional status predicts urinary continence recovery after radical prostatectomy
40. 695 Impact of stage migration on node positive prostate cancer rate and features: A 20-year, single institution analysis in men treated with extended pelvic lymph node dissection
41. 137 PHI (Prostate Health Index) and %p2PSA for prediction of prostate cancer in men younger than 60 years of age. A nested-case control study from PROpsa Multicentric European Study (PROMEtheuS project)
42. 918 Is robotic assisted radical prostatectomy the real alternative to active surveillance? Results of peri-operative and functional outcome analyses
43. 912 Comparison of PHI (Prostate Health Index) and PCA3 assay in the prediction of prostate biopsy (PBx) outcome in patients who have undergone initial and repeated prostatic biopsies
44. 150 Misclassification of micro-focus prostate cancer decreases with the extent of biopsy sampling. Importance of accurate detection
45. 909 Clinical cut-offs of isoform [-2]proPSA (p2PSA) derivatives, namely %p2PSA and PHI (Prostate Health Index) for guiding biopsy decision in Caucasian population
46. 971 Oncological and functional outcomes of patients eligible for active surveillance treated with radical prostatectomy
47. 910 Isoform [-2]proPSA (p2PSA) and its derivates, %p2PSA and PHI values differ between BPH, ASAP, HG-PIN and PCa in a set of contemporary men undergoing prostate biopsy
48. 278 Correlation of chronic histologic prostatic inflammation (CHPI) in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA and PHI (prostate health index) in men undergoing prostate biopsy for suspected PCa
49. 259 Serum isoform [-2]proPSA (p2PSA) and its derivates, %p2PSA and PHI (prostate health index), are more accurate than the reference standard test (PSA) in men scheduled for repeat biopsy
50. 1012 Evaluation of lymph node recurrent prostate cancer with integrated [11C]choline PET/CT in patients with PSA failure after radical prostatectomy: Validation by histological analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.